{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:55Z","timestamp":1786980295474,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T00:00:00Z","timestamp":1679011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23GM134482"],"award-info":[{"award-number":["K23GM134482"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23DE028010"],"award-info":[{"award-number":["K23DE028010"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This review was designed to compile the currently available evidence on the prophylactic use of gabapentin in the head and neck cancer patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted of PubMed, Web of Science, and Google Scholar to identify articles related to the use of prophylactic gabapentin in patients undergoing head and neck cancer therapy. Candidate studies were screened for inclusion and a subsequent bias assessment was conducted by multiple reviewers. Meta-analysis was conducted in cases in which the studies used compatible outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten studies were identified that met the inclusion criteria and were assessed for bias. Among the four small studies that examined pain prevention, 2 were positive and 2 were inconclusive. Three of the four studies examiniRDng opioid use noted less need for opioids in the treatment arm. Meta-analysis of the pertinent studies showed no difference in feeding tube placement (RD\u2009=\u20090.64%, 95%CI: (\u2212\u200925.8%, 27.1%),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.962) but substantially less weight loss among those in the treatment arm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prophylactic gabapentin appears to be a promising treatment option for preventing pain, reducing opioids, and reducing weight loss in patients undergoing head and neck cancer therapy. However, the studies on the treatment to date are small and several have a substantial risk of bias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-023-07683-w","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T04:02:46Z","timestamp":1679025766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"31","author":[{"given":"Loren E.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,17]]},"reference":[{"issue":"1","key":"7683_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"7683_CR2","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cncr.32583","volume":"126","author":"A Thompson-Harvey","year":"2020","unstructured":"Thompson-Harvey A et al (2020) Rising incidence of late-stage head and neck cancer in the United States. Cancer 126(5):1090\u20131101","journal-title":"Cancer"},{"issue":"6","key":"7683_CR3","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/hed.25650","volume":"41","author":"BR Campbell","year":"2019","unstructured":"Campbell BR et al (2019) Early onset oral tongue squamous cell carcinoma: associated factors and patient outcomes. Head Neck 41(6):1952\u20131960","journal-title":"Head Neck"},{"key":"7683_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.critrevonc.2015.11.010","volume":"99","author":"A Mirabile","year":"2016","unstructured":"Mirabile A et al (2016) Pain management in head and neck cancer patients undergoing chemo-radiotherapy: clinical practical recommendations. Crit Rev Oncol Hematol 99:100\u2013106","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"7683_CR5","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13(2):e58-68","journal-title":"Lancet Oncol"},{"issue":"4","key":"7683_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/COC.0000000000000896","volume":"45","author":"R Ganju","year":"2022","unstructured":"Ganju R et al (2022) Incidence and predictors of persistent opioid use in survivors of head and neck cancer treated with curative radiation. Am J Clin Oncol 45(4):161\u2013167","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"7683_CR7","doi-asserted-by":"publisher","first-page":"100583","DOI":"10.1016\/j.adro.2020.09.023","volume":"6","author":"S Zayed","year":"2021","unstructured":"Zayed S et al (2021) Risk of chronic opioid use after radiation for head and neck cancer: a systematic review and meta-analysis. Adv Radiat Oncol 6(2):100583","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"7683_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1191\/0269216304pm845ra","volume":"18","author":"MI Bennett","year":"2004","unstructured":"Bennett MI, Simpson KH (2004) Gabapentin in the treatment of neuropathic pain. Palliat Med 18(1):5\u201311","journal-title":"Palliat Med"},{"issue":"3","key":"7683_CR9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00455-014-9521-1","volume":"29","author":"HM Starmer","year":"2014","unstructured":"Starmer HM et al (2014) Effect of gabapentin on swallowing during and after chemoradiation for oropharyngeal squamous cell cancer. Dysphagia 29(3):396\u2013402","journal-title":"Dysphagia"},{"issue":"12","key":"7683_CR10","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1002\/hed.26407","volume":"42","author":"DK Smith","year":"2020","unstructured":"Smith DK et al (2020) Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation. Head Neck 42(12):3497\u20133505","journal-title":"Head Neck"},{"issue":"6","key":"7683_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.anl.2016.02.012","volume":"43","author":"T Kataoka","year":"2016","unstructured":"Kataoka T et al (2016) Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx 43(6):677\u2013684","journal-title":"Auris Nasus Larynx"},{"issue":"4","key":"7683_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ijrobp.2021.11.012","volume":"112","author":"A Cook","year":"2022","unstructured":"Cook A et al (2022) Randomized phase 3, double-blind, placebo-controlled study of prophylactic gabapentin for the reduction of oral mucositis pain during the treatment of oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 112(4):926\u2013937","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"7683_CR13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ijrobp.2022.03.038","volume":"113","author":"DK Smith","year":"2022","unstructured":"Smith DK, Murphy B (2022) In regard to Cook et al. Int J Radiat Oncol Biol Phys 113(5):1103\u20131104","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"7683_CR14","doi-asserted-by":"publisher","first-page":"e2212900","DOI":"10.1001\/jamanetworkopen.2022.12900","volume":"5","author":"SJ Ma","year":"2022","unstructured":"Ma SJ et al (2022) Association of gabapentin use with pain control and feeding tube placement among patients with head and neck cancer receiving chemoradiotherapy. JAMA Netw Open 5(5):e2212900","journal-title":"JAMA Netw Open"},{"issue":"6","key":"7683_CR15","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/hed.27035","volume":"44","author":"DR Gilley","year":"2022","unstructured":"Gilley DR et al (2022) Effectiveness of gabapentin in reducing opioid requirements after radiation in head and neck cancer in a single institution. Head Neck 44(6):1368\u20131376","journal-title":"Head Neck"},{"issue":"3","key":"7683_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00455-017-9783-5","volume":"32","author":"HM Starmer","year":"2017","unstructured":"Starmer HM et al (2017) One-year swallowing outcomes in patients treated with prophylactic gabapentin during radiation-based treatment for oropharyngeal cancer. Dysphagia 32(3):437\u2013442","journal-title":"Dysphagia"},{"issue":"2","key":"7683_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00455-015-9679-1","volume":"31","author":"W Yang","year":"2016","unstructured":"Yang W et al (2016) Predictive factors for prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement and use in head and neck patients following intensity-modulated radiation therapy (IMRT) treatment: concordance, discrepancies, and the role of gabapentin. Dysphagia 31(2):206\u2013213","journal-title":"Dysphagia"},{"issue":"7","key":"7683_CR18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/cncr.32676","volume":"126","author":"GM Hermann","year":"2020","unstructured":"Hermann GM et al (2020) A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer. Cancer 126(7):1480\u20131491","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07683-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T04:08:34Z","timestamp":1681531714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07683-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,17]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["7683"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07683-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,17]]},"assertion":[{"value":"8 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was exempted from the ethics review<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No identifiable information was used in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}